Caribou Biosciences Confirms Director Elections and Auditor

The latest announcement is out from Caribou Biosciences ( (CRBU) ).

On June 12, 2025, Caribou Biosciences, Inc. held its annual meeting of stockholders, where several key proposals were voted on. The election of two Class I directors, Scott Braunstein, M.D. and Ran Zheng, M.S., was confirmed, and the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, stockholders approved an amendment to the company’s certificate of incorporation to allow a reverse stock split and the potential adjournment of the annual meeting if necessary, although the latter was not needed as there was a quorum and sufficient votes for the proposals.

The most recent analyst rating on (CRBU) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Caribou Biosciences stock, see the CRBU Stock Forecast page.

Spark’s Take on CRBU Stock

According to Spark, TipRanks’ AI Analyst, CRBU is a Neutral.

Caribou Biosciences has significant financial challenges, with declining revenues and large operational losses negatively impacting its score. While technical indicators show some positive short-term momentum, the overall valuation remains unattractive due to negative earnings. The strong equity position provides some stability, but the company needs to address its financial health to improve its stock performance.

To see Spark’s full report on CRBU stock, click here.

More about Caribou Biosciences

Caribou Biosciences, Inc. operates in the biotechnology industry, focusing on the development of genome editing technologies and therapies.

Average Trading Volume: 1,094,157

Technical Sentiment Signal: Sell

Current Market Cap: $109.7M

See more insights into CRBU stock on TipRanks’ Stock Analysis page.